Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. by Morham, S G et al.
MOLECULAR AND CELLULAR BIOLOGY, Dec. 1996, p. 6804–6809 Vol. 16, No. 12
0270-7306/96/$04.0010
Copyright q 1996, American Society for Microbiology
Targeted Disruption of the Mouse Topoisomerase I Gene
by Camptothecin Selection
SCOTT G. MORHAM,* KIMBERLY D. KLUCKMAN, NECTARIOS VOULOMANOS,
AND OLIVER SMITHIES
Department of Pathology, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599-7525
Received 30 May 1996/Returned for modification 8 July 1996/Accepted 21 August 1996
Topoisomerase I has ubiquitous roles in important cellular functions such as replication, transcription, and
recombination. In order to further characterize this enzyme in vivo, we have used gene targeting to inactivate
the mouse Top-1 gene. A selection protocol using the topoisomerase I inhibitor camptothecin facilitated isola-
tion of embryonic stem cell clones containing an inactivated allele; isolation of correctly targeted clones was
enhanced 75-fold over that achieved by normal selection procedures. The disrupted Top-1 allele is embryonic
lethal when homozygous, and development of such embryos fails between the 4- and 16-cell stages. Both sperm
and oocytes containing the inactive allele maintain viability through the fertilization point, and thus gene ex-
pression of topoisomerase I is not required for gamete viability. These studies demonstrate that topoisomerase
I is essential for cell growth and division in vivo. The Top-1 gene was also shown to be linked to the agouti locus.
Eukaryotic topoisomerase I has a key role in many funda-
mental biological processes. The enzyme alters DNA topology
by catalyzing transient single-stranded breakage of the phos-
phodiester backbone; this event allows passage of the intact
strand through the break site, and subsequent religation of the
nicked strand reforms the intact helix. Both positive and neg-
ative supercoils can be relaxed by eukaryotic topoisomerase I,
and the linking number of the DNA can be changed by incre-
ments as small as one. This simple type of topological manip-
ulation is known to be a crucial process for basic DNA and
RNA metabolism in mammalian cells (40, 41).
A variety of studies, both in vitro and in vivo, indicate the
importance of topoisomerase I in cellular function. The en-
zyme is necessary for efficient simian virus 40 replication in
vitro (12, 42, 43), and Saccharomyces cerevisiae TOP1 mutants
have delayed onsets of DNA short-chain elongation during
early S phase (15). Topoisomerase I is known to interact with
regions of actively transcribed chromatin (8, 34, 35) and has
also been found to be an essential component of some in vitro
transcriptional systems (18). In addition, inactivation of TOP1
affects the rate of transcription in S. cerevisiae (5).
Experiments with yeast TOP1 mutants showed that topo-
isomerase I was dispensable for cell growth (38, 39). This is not
the case with Drosophila melanogaster, in which topoisomerase
I is required for development past the blastocyst stage (21).
The gene may thus be essential in more-complex eukaryotes.
DNA topoisomerase I is considered an attractive target for
cancer chemotherapy. Levels of the enzyme are found to be
elevated in several types of leukemia, lymphoma, and colon
carcinoma cells (9, 27), and a variety of promising antineoplas-
tic agents that inhibit topoisomerase I activity are currently
under examination (3, 9). Several such agents are derived from
the cytotoxic plant alkaloid camptothecin (CPT), including to-
potecan, 9-amino-CPT, and CPT-11.
CPT seems to act by stabilizing the topoisomerase I-DNA
covalent intermediate, significantly slowing the reclosure step
of the nicking-closing reaction (11, 26). Cellular cytotoxicity of
CPT is associated with persistent double-stranded breaks in
replicating cellular DNA that are postulated to be highly lethal
(30). Resulting DNA damage can lead to cell cycle arrest
and/or cell death by apoptosis (7). Stepwise exposure of several
cell types to increasing levels of CPT has resulted in the iso-
lation of drug-resistant cell lines. These lines have reduced
topoisomerase I levels (13, 33), mutations in the coding region
of the gene, or both (19, 36). Point mutations resulting in CPT
resistance and reduced enzymatic activity have been used to
detect structure-function relationships between various regions
of the protein and drug resistance. The lack of mutations
completely eliminating topoisomerase I activity suggests an
important role for the enzyme in cellular viability.
Although many studies link topoisomerase I to important
cellular functions, the precise role of the enzyme in these
processes remains obscure. In order to investigate whether the
gene is essential for mammalian development, we have used
gene targeting to develop mice in which Top-1 has been inter-
rupted. To accomplish this, the topoisomerase I inhibitor CPT
was used to develop a procedure for selection of homologous
recombinants in which one copy of the gene has been dis-
rupted.
MATERIALS AND METHODS
Cloning the topoisomerase I gene and construction of the targeting vector.
Genomic DNA was isolated from E14TG2a (10) mouse embryonic stem (ES)
cells and partially digested with MboI. Fragments of approximately 15 kb were
isolated and used to make a library in lambda phage Charon 35 (22). Primers
corresponding to highly conserved regions of exon 15 of the human topoisom-
erase I gene (4, 20) were used for PCR amplification of the mouse gene (1), thus
generating a 150-bp probe for screening use. The primers used were from the 59
region of exon 15 (59-GCTCTGAGAGCAGGCAATGAAAA-39) and the 39
region of the exon 15 coding sequence (59-ATGGAGTCCTTCCCGAGGAAG
TCAAA-39); the resulting probe corresponds to amino acid residues 486 to 535
(4). Clones containing portions of the topoisomerase I gene were isolated, and
two fragments (4.5-kb BglII and 6.0-kb BamHI fragments) containing exon 15
were subcloned (Fig. 1A). A 3.8-kb BglII-PstI fragment and a 1.4-kb BglII-
HindIII fragment were then used to create the targeting vector, pTGT-2 (Fig. 1A
and B).
Cell culture, electroporation, and selection. BK4 cells (a subclone of
E14TG2a, provided by B. Koller, University of North Carolina at Chapel Hill)
were cultured on murine embryonic fibroblasts in Dulbecco modified Eagle
medium-high glucose (DMEM-H) (Life Technologies)–100 mM b-mercapto-
ethanol–2 mM L-glutamine. The cells were trypsinized and resuspended in 0.04
ml of DMEM-H. Electroporation was carried out in the presence of 2 to 5 nM
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pTGT-2 plasmid which had been linearized with SacII; a 1-s discharge from a
200-mF capacitor charged to 300 V was used. Selection with G418 and ganciclovir
was carried out as described elsewhere (23). Half of each clone was picked with
a micropipette and placed in a 24-well tissue culture plate overnight. The next
day, the colony was trypsinized and expanded for use or frozen in 50% serum–
40% DMEM-H–10% dimethyl sulfoxide (DMSO) at 2808C. The other half of
the clone was utilized for genotypic PCR analysis.
In a separate experiment, cell colonies surviving G418-ganciclovir selection
were dispersed with trypsin, replated, and allowed to grow for 3 days. The cells
were then exposed to DMEM-H containing 250 nM, 500 nM, or 1 mM CPT
(made from a 1 mM stock in DMSO) to directly select for cells containing
reduced topoisomerase I activity. The selection was maintained for 7 days, at
which time CPT-resistant clones were chosen from each plate. Cells from each
individual plate were regarded as clonal, since the clonality of cells within an
individual plate could not be assessed. Clones were picked with a micropipette
and placed in a 24-well tissue culture plate. Colonies were subsequently ex-
panded for use or frozen in 50% serum–40% DMEM-H–10% DMSO at 2808C.
Targeted cells heterozygous for the inactivated Top-1 allele were further se-
lected in higher concentrations of G418 by the method of Mortenson et al. (25)
in an attempt to select clones homozygous for the targeted allele.
Genotypic analysis by PCR and Southern blotting. Potential recombinant
clones were initially screened by recording the presence of a PCR product
diagnostic for a correct homologous recombination event (14). The two primers
used were derived from the neo gene (59-ACGCGTCACCTTAATATGCG-39)
and from an intron region that was not included in the targeting construct
(59-ATGTTGTTGTCTTGGGTTCTG-39) (Fig. 1C). DNAs from clones that
had undergone homologous recombination (as judged by the amplification of the
correct PCR fragment) were then used for Southern blot analysis to confirm that
Top-1 had been disrupted.
The genotypes of the mice were determined by using DNA isolated from their
tails. Genomic DNA totalling 8 to 10 mg was digested with PstI or BamHI
overnight and applied to a 0.8% agarose gel. After separation by agarose gel
electrophoresis, the DNA was transferred to Hybond nylon membranes. The
membranes were probed with a 2.0-kb BamHI-KpnI fragment from the Top-1
genomic clone (Fig. 1A) labeled with 32P. The membranes were washed and
exposed to Kodak XAR film overnight with an intensifying screen.
Analysis of CPT resistance in heterozygous ES cells.Wild-type and heterozy-
gous mutant ES cells were grown without feeder cells, and nuclear extracts were
prepared from these cells as described by Tanizawa and Pommier (37). The
nuclear extracts containing topoisomerase I were then assayed for CPT sensitiv-
ity as previously described (24).
Microinjection and derivation of a heterozygous mouse line. Cells from one of
the targeted clones were microinjected into C57BL/6J (B6) host blastocysts and
implanted in pseudopregnant female recipients to generate chimeric mice. A
male mouse that transmitted the 129 germ line to his progeny at 100% frequency
was identified. This male was bred to B6 females, and approximately 50% of his
F1 pups were heterozygous for one wild-type and one disrupted allele. The
heterozygous F1 progeny were then interbred to obtain F2 mice. These mice were
used for further studies.
Quantitation of topoisomerase I levels. Enzyme quantitation was done by
Western blot (immunoblot) analysis. Equivalent weights of liver tissue were
isolated from wild-type and heterozygous F2 mice, and salt-soluble nuclear pro-
tein fractions were obtained as described by Tanizawa and Pommier (37). A
50-mg amount of total salt-soluble nuclear protein from wild-type and heterozy-
gous animals was separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis. The protein was then transferred to nitrocellulose by using a
Bio-Rad electroblotter and transfer buffer (39 mM glycine, 48 mM Tris, 0.037%
SDS, and 20% methanol) at 48C and 100 mA.
After protein transfer, the nitrocellulose membrane was incubated in blocking
solution (3% nonfat dried milk in Tris-buffered saline [TBS], 50 mM Tris-HCl
[pH 8.0], 150 mM NaCl) for 2 h with gentle agitation. All incubations were done
at room temperature. The membrane was then incubated with an anti-topoisom-
erase I antibody (anti-Scl-70 antigen antibody, purchased from Immunovision
Inc.) diluted 1:5,000 in blocking solution. The blot was washed in 200 ml of TBS
three times before incubation with a secondary reagent (goat anti-human poly-
valent immunoglobulin–alkaline phosphatase conjugate or –horseradish peroxi-
dase conjugate, purchased from Sigma Immunochemicals, St. Louis, Mo.) at a
1:10,000 dilution in TBS for 1 h. The membrane was then washed three times
with TBS. Protein was detected by incubation with either a luminescent or a
chromogenic substrate (31). Densitometry was used to determine the relative
amounts of protein from wild-type and heterozygous cells.
Collection of embryos. F2 females heterozygous for the topoisomerase I-defi-
cient allele were superovulated with 5 U of pregnant mare serum gonadotropin
and given 5 U of human chorionic gonadotropin within 45 to 48 h. They were
then mated with heterozygous F1 males. Pregnant females at 3 to 4 days of
gestation (vaginal plug counted as day 0) were euthanized by cervical dislocation.
The oviducts were removed and flushed with modified M2 medium (Sigma
Chemicals, St. Louis, Mo.). One- to 64-cell embryos were collected and placed in
drops of M2 medium covered with paraffin oil.
Microscope slide preparation.Detergent-cleaned glass microscope slides were
coated twice with a 2-mg/ml poly-L-lysine hydrobromide solution (molecular
weight, .300,000; Sigma Chemicals) dissolved in distilled water (32).
Embryo preparation. The zona pellucida was removed with acidic Tyrodes
solution (Sigma Chemicals). The embryos were allowed to equilibrate in M2
medium for 30 min and were washed with phosphate-buffered saline (pH 7.5)
without calcium or magnesium (PBS). The tissue culture plate was coated with
1% Bacto-agar to prevent adhesion of the embryos (32).
Embryo fixation and permeabilization. A 7-ml drop of PBS was placed on the
coated microscope slide. Embryos were dispensed into the drop. After a 5-min
incubation at 378C in a humidified chamber, 1 ml of 3.5% formaldehyde–0.1%
Triton X-100 solution was added and the slide was placed at room temperature
for 5 min. A 1-ml volume of 2.5% glutaraldehyde was then added. It was found
to be important to keep the slides in a humidified chamber to prevent evapora-
tion of solutions. After 5 min, the slides were submersed in PBS.
Immunofluorescence staining of embryos. Affixed embryos were immersed in
blocking solution (15% bovine serum albumin, 0.1% Triton X-100, and 10%
horse serum in PBS) for 1 h at room temperature, at which time they were
incubated with an anti-topoisomerase I antibody (anti-Scl-70 antigen antibody;
Immunovision Inc.) at a 1:100 dilution in blocking solution. The embryos were
washed three times in 50 ml of blocking solution before incubation with a
secondary reagent (goat anti-human polyvalent immunoglobulin–alkaline phos-
phatase conjugate; Sigma Immunochemicals). The three washes were repeated,
and the embryos were then examined by immunofluorescence microscopy.
RESULTS
Enrichment for recombinant Top-1 clones by using CPT in
a selection protocol and attempts to isolate homozygous mu-
tant ES cells. After electroporation of the targeting construct
into BK4 cells and selection using G418 and ganciclovir, 192
resultant colonies were screened by PCR for clones having
undergone homologous recombination events. Cell lines hav-
ing undergone the planned targeting event generate a 1.8-kb
PCR product when the two primers illustrated in Fig. 1C are
used. Two colonies were detected, yielding a frequency of 1/96.
In a separate set of experiments, a selection protocol based
on the topoisomerase I-specific cellular toxin CPT was used to
attempt selection of homozygous recombinants. In these ex-
periments, cells electroporated with the targeting construct
were first selected with G418 and ganciclovir; approximately
100 resistant colonies per plate were found. Cells from nine
FIG. 1. Disruption of the mouse Top-1 gene. (A) Part of the wild-type Top-1
gene. Exon 15 (black box) and the BamHI-KpnI fragment used as a probe for
Southern analysis (double arrow) are indicated. B, Ba, H, K, P, and S, BglII,
BamHI, HindIII, KpnI, PstI, and SalI, respectively. (B) The targeting construct.
Neomycin resistance (NEO) and thymidine kinase (TK) genes, oriented as in-
dicated by the arrows, and plasmid sequence (wavy line) (not drawn to scale) are
shown. The most 59 SalI site in the construct is from the lambda phage vector.
(C) The targeted Top-1 locus, with Neo replacing exon 15. PCR primers used to
identify targeted cell lines are indicated (arrowheads).
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plates were then dispersed with trypsin and allowed to grow for
3 days in DMEM. At this time, the plates, which were approx-
imately 70% confluent, were selected with various concentra-
tions of CPT (250 nM, 500 nM, and 1 mM) in an attempt to
select colonies completely lacking topoisomerase I activity.
Only the 250 and 500 nM concentrations yielded colonies; all
cells were killed by the 1 mM concentration. One colony from
each of nine plates was then screened by PCR, and none of the
nine independently isolated colonies were found to be homozy-
gous for the inactivated allele. However, seven of the nine
colonies were heterozygous for the inactive allele. Thus, al-
though the protocol failed to select homozygous mutant
clones, the isolation of Top-1 heterozygous cell lines was sig-
nificantly enhanced by selection in the presence of 250 or 500
nM CPT. Thus, a 75-fold enrichment of correctly targeted
homologous recombinants was obtained by using G418, ganci-
clovir, and subsequent CPT selection (7 of 9), compared with
G418 and ganciclovir selection alone (2 of 192).
We also attempted to isolate cells homozygous for the tar-
geted allele according to the protocol of Mortenson et al. (25),
which uses a G418 concentration higher than the original se-
lection concentrations to select mutants homozygous for the
neo-containing targeted allele. Even though we were successful
with this protocol in isolating homozygous mutants for both
Ptgs-1 and Ptgs-2 (23a), thus demonstrating the efficacy of the
method in our hands, all attempts to isolate homozygous Top-1
mutants were unsuccessful.
Confirmation of gene targeting and germ line transmission
from chimeras to F1 progeny. Genomic DNAs from the PCR-
positive cell lines were digested with PstI or BamHI for South-
ern blot analysis. Correctly targeted cell lines generate a 2.6-kb
PstI fragment corresponding to the interrupted allele and a
2.0-kb PstI fragment corresponding to the wild-type allele, or a
2.2-kb BamHI fragment corresponding to the interrupted al-
lele and a 6.2-kb BamHI fragment corresponding to the wild-
type allele (Fig. 1A and B). One of the targeted cell lines (Fig.
2) was injected into B6 blastocysts. This cell line gave rise to
male chimeric animals which, when mated to B6 females, sub-
sequently passed the targeted allele to their F1 129/B6 off-
spring. F1 heterozygotes were interbred, and Southern blot
analysis of genomic DNAs from their F2 progeny showed the
2.6- and/or 2.0-kb PstI fragments expected for the wild-type or
heterozygous genotypes (Fig. 2A). The expected 6.2- and/or
2.2-kb BamHI fragments expected for wild-type and heterozy-
gous genotypes were also observed (Fig. 2B).
Selection in CPT does not affect subsequent development of
ES cells. A cell line that had been selected in 500 nM CPT was
subsequently used for injection into blastocysts. The resultant
chimeras displayed no overt pathology and were able to pass
the 129 lineage on to a subsequent generation. This demon-
strates that ES cells selected in CPT can retain their totipotent
ability to recapitulate all necessary tissue types.
Heterozygotes have cellular levels of topoisomerase I lower
than that of the wild type. Quantitation of topoisomerase I
levels in F2 animals was carried out by Western blotting. Six
wild-type and six heterozygous animals were analyzed. An av-
erage of 45% reduction in protein levels was observed in the
heterozygotes as measured by densitometry. A representative
Western blot showing topoisomerase I levels for two individual
wild-type animals (lanes1/1) and two individual heterozygous
animals (lanes 1/2) is shown in Fig. 3.
The remaining allele in the heterozygous mutant cell line
remains CPT sensitive. In order to determine whether the
wild-type allele in the heterozygous mutant cell line had also
undergone a mutational event (resulting in CPT resistance),
nuclear extracts from both wild-type and heterozygous mutant
ES cells were assayed for CPT sensitivity (data not shown).
Equivalent amounts of nuclear extracts from heterozygous and
wild-type ES cells were assayed for strand breakage in the
absence and presence of CPT. Both extracts demonstrated
increased strand breakage in the presence of CPT, indicating
that the other allele in the ES cell line heterozygous for the
disrupted allele had not been mutated to a CPT-resistant form.
Titration of the nuclear extract demonstrates that there is less
strand breakage activity in the mutant than in the wild type.
This would be expected, since only one copy of the wild-type
allele is present in heterozygous cells. Western blotting con-
firms a reduced level of topoisomerase I in heterozygous cells
(Fig. 3).
Genotypic analysis of F2 progeny from heterozygous F1 mat-
ings. The genotypes of progeny from F1 heterozygous females
mated to heterozygous F1 males were analyzed after Southern
FIG. 2. (A) Autoradiogram from a Southern blot of mouse genomic DNA
digested with PstI showing the expected fragments for the wild-type (2.0 kb) and
targeted (2.6 kb) alleles as indicated by the arrows. (B) Autoradiogram from a
Southern blot of mouse genomic DNA digested with BamHI showing the ex-
pected fragments for the wild-type (6.2 kb) and targeted (2.2 kb) alleles indicated
by the arrows. Lanes ES, T, and 1/2, genomic DNA from the parental ES cell
line, the targeted ES cell line, and a heterozygous Top-1 mutant mouse, respec-
tively. The radioactive probe used for detection was a KpnI fragment from the
genomic clone of Top-1.
FIG. 3. Western blot of salt-soluble nuclear protein from wild-type and het-
erozygous mutant Top-1 liver cells. Lanes: 1/1 and 1/2, nuclear protein frac-
tions (50 mg per lane) from two individual wild-type and two individual heterozy-
gous mutant mice, respectively; Std, purified HeLa topoisomerase I standard.
Positions of molecular mass markers are indicated on the right. The position of
the full-size topoisomerase I protein (Topo I) is indicated on the left.
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blotting. No homozygotes were found among the 125 F2 prog-
eny genotyped. Thus, the Top-1 inactivated allele is lethal when
homozygous. However, the genotypic ratios of the progeny
lead to some interesting corollaries. The ratio of wild-type to
heterozygous progeny at weaning (3 weeks after birth) was
41/84, which does not differ from the expected ratio of 1:2 (P.
0.5). This shows that both sperm and oocytes containing the
inactive allele are derived from a productive gametogenesis
and maintain their viability through fertilization. Thus, gene
expression of topoisomerase I is not required for sperm or
oocyte viability until after fertilization occurs. We find that a
haploid complement of the enzyme is not lethal or obviously
deleterious for the animal.
Topoisomerase I is linked to the agouti locus. Mouse strain
129 has a recessive wild-type allele (a) at the agouti locus.
Strain B6 is homozygous for the dominant mutant allele (A).
Inspection of the coat colors of the heterozygotes allows the
linkage of Top-1 to the agouti locus (A) to be determined. Of
68 mice heterozygous for the targeted Top-1 mutation, 4 had
solid black coats and 64 were agouti; of 33 wild-type mice, 2
were agouti and 33 were black. Both ratios, 4 of 68 and 2 of 33,
indicate a 6% recombination frequency, i.e., a map distance of
approximately 13 centimorgans between the agouti locus (A)
and Top-1. This is in agreement with current data which dem-
onstrate that both agouti and Top-1 reside on mouse chromo-
some 2 (16, 44).
Determination of lethality in early-stage embryos. Embryos
were isolated from superovulated females that had been bred
in either Het 3 Het or WT 3 WT crosses (where Het is
heterozygote and WT is wild type). In order to determine at
what stage homozygous embryos become inviable, we used
immunofluorescence to detect topoisomerase I in the nuclei of
embryos at various stages of development. The embryos were
fixed and treated with human anti-topoisomerase I antibody,
and detection was accomplished by using a goat anti-human
antibody conjugated with fluorescein. Embryos were also
stained with bisbenzimide for visualization of DNA. All 25
Het 3 Het embryos at the .32-cell stage were found to con-
tain topoisomerase I in all nuclei, as were all 30 Het 3 Het
embryos at the 16-cell stage. Seven of 52 embryos from the
eight-cell stage and 6 of 21 four-cell-stage Het 3 Het embryos
were found to lack topoisomerase I (Fig. 4C), even though all
the nuclei were readily visible with bisbenzimide staining (Fig.
4A). However, all 28 two-cell-stage Het 3 Het embryos con-
tained topoisomerase I. The nuclei of all WT 3 WT embryos
at all stages were visible with bisbenzimide staining (Fig. 4B),
and they also contained topoisomerase I in all nuclei (Fig. 4D).
These data show that homozygous mutants develop to the 4- or
8-cell stage but all fail to reach the 16-cell stage.
DISCUSSION
With all gene targeting procedures currently in use, some
type of selection is necessary to allow the isolation of recom-
binants. Here, we have used a selection protocol for the isola-
tion of a topoisomerase I knockout allele that depends on a
dominant selection against cells containing wild-type levels of
topoisomerase I. The selection protocol uses a protein-specific
toxin as the selective agent. CPT is such an agent for topo-
isomerase I (2, 11, 26, 30), and its use greatly simplified our iso-
lation of cells heterozygous for inactivation of the Top-1 allele.
The effectiveness of the approach is exemplified by the follow-
FIG. 4. Cytological analysis of wild-type (C and D) and topoisomerase-deficient mutant (A and B) embryos. Embryos were fixed with formaldehyde and stained
with bisbenzimide (A and C) and anti-Scl-70, an antitopoisomerase antibody (B and D).
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ing: only 2 of 192 G418- and ganciclovir-selected clones (1%)
were found to have undergone the desired recombination,
whereas 7 of 9 of the clones selected first with G418-ganciclovir
and then with CPT (77%) gave the desired homologous re-
combinant. This represents a 75-fold increase in selection ef-
ficiency.
Toxins specific to other enzymes might be used to select tar-
geted clones in conjunction with the more traditional selection
methods using G418 and ganciclovir. This eliminates much of
the more laborious genotypic screening usually needed to iso-
late targeted clones. Our success using CPT as a selection
agent validates this type of approach and may thus have a
broad utility in developing selection procedures for specific
gene-targeting events. Indeed, by using an enzyme-specific
toxin selection protocol, it may be possible to isolate ES cell
clones homozygous for the targeted allele without further
steps.
We have demonstrated that the untargeted topoisomerase I
allele isolated by our CPT selection protocol is sensitive to
CPT in vitro (data not shown). In addition, heterozygous cells
contain a reduced level of topoisomerase I (Fig. 3). This sug-
gests that a lower level of topoisomerase I protects cells from
the drug, a contention supported by data from cell selection
experiments using CPT (13, 33). These data from our experi-
ments do not, however, exclude the possibility that the nontar-
geted allele harbors a subtle mutation which renders it partially
resistant to CPT. In addition (for G418-, ganciclovir-, and
CPT-selected cells), we cannot rule out the presence of other
mutations elsewhere in the genome affecting CPT resistance.
Note, however, that the wild-type allele present in the het-
erozygous F1 and F2 animals comes from the B6 lineage of the
female that was mated to the chimera and is thus a wild-type
B6 Top-1 gene.
There is evidence that CPT causes differentiation in various
cell lines (17), although the reason for this is unknown at
present. However, in our experiments, recombinant ES cells
selected in 500 nM CPT retained their totipotent ability to
develop into a whole organism; thus, they show no evidence of
having differentiated after treatment.
In Escherichia coli, inactive mutants of the topoisomerase I
gene are isolated only in the presence of compensatory muta-
tions in the topoisomerase II gene or other genes (6, 28, 29).
Topoisomerase I is not essential in the eukaryotes S. cerevisiae
and Schizosaccharomyces pombe (38, 39) but is required for
development past the blastocyst stage in D. melanogaster (21).
In addition, cellular selection in vitro with CPT results in
mutations which reduce cellular topoisomerase I levels (13, 33)
or render the enzyme resistant to the drug (19, 36). The gene
may thus be essential in more-complex eukaryotes.
The importance of topoisomerase I to cellular function in
mammals has been demonstrated in the present study by the
deleterious effect of its absence on the developing mouse em-
bryo. Thus, failure of Top-1 2/2 embryos to continue devel-
opment at the 4- to 16-cell stage is strongly suggestive that
topoisomerase I is essential for cell division and that enzyme
expression is required very early after fertilization. Since we
can detect the presence of the enzyme in all two-cell Het 3
Het embryos, it is likely that a maternal complement of topo-
isomerase I or Top-1 message is present in oocytes; this allows
development to the four- to eight-cell stage in homozygous
mutant embryos. However, because no new topoisomerase I
message can be synthesized in Top-1 2/2 cells, this maternal
complement of enzyme eventually becomes limiting, and fur-
ther cell division ceases. In any case, it is clear that topoisom-
erase I is essential for development in the mouse.
Our failure to isolate a homozygous ES cell line by using
either of two powerful selection procedures supports the prop-
osition that Top-1 is essential for cell growth in tissue culture.
Thus, while both an increased level of G418 (25) and a high
level of CPT (1 mM) were used to attempt selection of ho-
mozygous mutant ES cells, neither yielded surviving colonies.
Although this does not directly demonstrate that cells require
topoisomerase I for growth, the inability to isolate cells carry-
ing homozygous targeted alleles strongly suggests that Top-1 is
necessary for cellular division.
Breeding data also demonstrate the essential nature of the
topoisomerase I gene, since no animals homozygous for the
mutation have been found among the 125 progeny examined.
However, because the numbers of heterozygotes and wild-type
animals obtained in the F1 by F1 matings do not differ from the
expected 2:1 ratio, the data also demonstrate that topoisom-
erase I is not essential for gamete viability. If both the sperm
and the oocytes were inviable in the mutant haploid state, only
wild-type pups would be born. If either the sperm or the oo-
cytes were inviable, then the ratio of heterozygotes to wild type
would be 1:1. Breeding data also indicate that the topoisom-
erase I gene is linked to the agouti gene (A) at a distance of
approximately 13 centimorgans.
Our demonstration that topoisomerase I is a crucial enzyme
for cell growth and embryo development suggests that cell lines
derived from the heterozygous animals will be useful for mu-
tagenesis studies to investigate the mechanisms of topoisom-
erase I action. Since such cell lines contain only a single copy
of the wild-type Top-1 allele, the isolation of mutants is sim-
plified and hence a variety of complementation studies can be
attempted. Temperature-sensitive mutant cells would provide
a valuable tool for discerning how the enzyme acts in replica-
tion, transcription, and recombination.
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